메뉴 건너뛰기




Volumn 3, Issue 3, 2014, Pages 143-148

Recommendations for the regulation of biosimilars and their implementation in Latin america

Author keywords

Biological products; Biosimilarity; Biosimilars; Latin america; reference biotherapeutic product (RBP); Regulatory pathways

Indexed keywords


EID: 85008254473     PISSN: 20336403     EISSN: 20336772     Source Type: Journal    
DOI: 10.5639/gabij.2014.0303.032     Document Type: Review
Times cited : (29)

References (38)
  • 1
    • 67449138587 scopus 로고    scopus 로고
    • Biosimilars-science, status, and strategic perspective
    • Kresse GB. Biosimilars-science, status, and strategic perspective. Eur J Pharm Biopharm. 2009;72(3):479-86.
    • (2009) Eur J Pharm Biopharm , vol.72 , Issue.3 , pp. 479-486
    • Kresse, G.B.1
  • 2
    • 85032470394 scopus 로고    scopus 로고
    • World Health Organization. Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva, 19-23 October, 2009 [homepage on the Internet]. 2010 Apr 6 [cited 2014 May 27]. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
  • 3
    • 77949469515 scopus 로고    scopus 로고
    • Are biosimilars really generics?
    • Misra A. Are biosimilars really generics? Expert Opin Biol Ther. 2010;10(4):489-94.
    • (2010) Expert Opin Biol Ther , vol.10 , Issue.4 , pp. 489-494
    • Misra, A.1
  • 4
    • 77953343625 scopus 로고    scopus 로고
    • Biosmilars: current status and future directions
    • Roger SD. Biosmilars: current status and future directions. Expert Opin Biol Ther. 2010;10(7):1011-8.
    • (2010) Expert Opin Biol Ther , vol.10 , Issue.7 , pp. 1011-1018
    • Roger, S.D.1
  • 5
    • 47349092310 scopus 로고    scopus 로고
    • Current legal, regulatory, and scientific implications of biosimilars
    • Wenzel RG. Current legal, regulatory, and scientific implications of biosimilars. Introduction. Am J Health Syst Pharm. 2008;65(14 Suppl 6):S1. doi:10.2146/ajhp080209
    • (2008) Introduction. Am J Health Syst Pharm , vol.65 , pp. S1
    • Wenzel, R.G.1
  • 6
    • 84896883598 scopus 로고    scopus 로고
    • Biosimilars: how similar?
    • Mar
    • Strand V, Cronstein B. Biosimilars: how similar? Intern Med J. 2014 Mar;44(3):218-23. doi:10.1111/imj.12292
    • (2014) Intern Med J , vol.44 , Issue.3 , pp. 218-223
    • Strand, V.1    Cronstein, B.2
  • 11
    • 84950998637 scopus 로고    scopus 로고
    • Biosimilar monoclonal antibodies approved for use in the EU
    • Thorpe R. Biosimilar monoclonal antibodies approved for use in the EU. Generics and Biosimilars Initiative Journal (GaBI Journal). 2014;3(1):9. doi:10.5639/gabij.2014.0301.004
    • (2014) Generics and Biosimilars Initiative Journal (GaBI Journal) , vol.3 , Issue.1 , pp. 9
    • Thorpe, R.1
  • 14
    • 84874472951 scopus 로고    scopus 로고
    • Biosimilars and market access: a question of comparability and costs?
    • Simoens S, Verbeken G, Huys I. Biosimilars and market access: a question of comparability and costs? Target Oncol. 2012;7(4):227-31.
    • (2012) Target Oncol , vol.7 , Issue.4 , pp. 227-231
    • Simoens, S.1    Verbeken, G.2    Huys, I.3
  • 15
    • 85032514728 scopus 로고    scopus 로고
    • Shapiro M. Quality Considerations for biosimilars. Federal Drug Administration. Division of Monoclonal Antibodies/OBP/OPS. Advisory Committee for Pharmaceutical Science and Clinical Pharmacology. 8 Aug 2012. Presentation [homepage on the Internet]. 2012 Aug 16 [cited 2014 May 17]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM315764.pdf
  • 16
    • 85032465735 scopus 로고    scopus 로고
    • European Medical Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on the choice of the non-inferiority margin. London, 27 July 2005. Doc. Ref. EMEA/CPMP/EWP/2158/99 [homepage on the Internet]. 2012 Aug 16 [cited 2014 May 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003636.pdf
  • 17
    • 45949108207 scopus 로고    scopus 로고
    • WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007
    • Joung J, Robertson JS, Griffiths E, Knezevic I. WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007. Biologicals. 2008;36(4):269-76.
    • (2008) Biologicals , vol.36 , Issue.4 , pp. 269-276
    • Joung, J.1    Robertson, J.S.2    Griffiths, E.3    Knezevic, I.4
  • 18
    • 0034754477 scopus 로고    scopus 로고
    • Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial
    • Nov
    • Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001 Nov;121(5):1088-94.
    • (2001) Gastroenterology , vol.121 , Issue.5 , pp. 1088-1094
    • Sandborn, W.J.1    Hanauer, S.B.2    Katz, S.3    Safdi, M.4    Wolf, D.G.5    Baerg, R.D.6
  • 19
    • 33846242958 scopus 로고    scopus 로고
    • Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial
    • Jan
    • Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007 Jan;132(1):52-65.
    • (2007) Gastroenterology , vol.132 , Issue.1 , pp. 52-65
    • Colombel, J.F.1    Sandborn, W.J.2    Rutgeerts, P.3    Enns, R.4    Hanauer, S.B.5    Panaccione, R.6
  • 20
    • 77953701867 scopus 로고    scopus 로고
    • Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study
    • Jun
    • Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis. 2010 Jun;69(6):1129-35.
    • (2010) Ann Rheum Dis , vol.69 , Issue.6 , pp. 1129-1135
    • Keystone, E.1    Genovese, M.C.2    Klareskog, L.3    Hsia, E.C.4    Hall, S.5    Miranda, P.C.6
  • 21
    • 67650379733 scopus 로고    scopus 로고
    • GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
    • Jul 18
    • Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, et al; GO-AFTER study investigators. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009 Jul 18;374(9685):210-21.
    • (2009) Lancet , vol.374 , Issue.9685 , pp. 210-221
    • Smolen, J.S.1    Kay, J.2    Doyle, M.K.3    Landewé, R.4    Matteson, E.L.5    Wollenhaupt, J.6
  • 22
    • 68049099274 scopus 로고    scopus 로고
    • Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis
    • Aug
    • Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009 Aug;60(8):2272-83.
    • (2009) Arthritis Rheum , vol.60 , Issue.8 , pp. 2272-2283
    • Emery, P.1    Fleischmann, R.M.2    Moreland, L.W.3    Hsia, E.C.4    Strusberg, I.5    Durez, P.6
  • 23
    • 80051984166 scopus 로고    scopus 로고
    • Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations
    • Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs. 2011;71:1527-36.
    • (2011) Drugs , vol.71 , pp. 1527-1536
    • Dranitsaris, G.1    Amir, E.2    Dorward, K.3
  • 24
    • 85032492210 scopus 로고    scopus 로고
    • European Medical Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London, 22 February 2006. EMEA/CHMP/BMWP/42832/2005 [homepage on the Internet]. 2006 Mar 8 [cited 2014 May 27]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003920.pdf
  • 27
    • 84887860699 scopus 로고    scopus 로고
    • Review on the worldwide regulatory framework for biosimilars focusing on the Mexican case as an emerging market in Latin America
    • Dec
    • Ibarra-Cabrera R, Mena-Pérez SC, Bondani-Guasti A, García-Arrazola R. Review on the worldwide regulatory framework for biosimilars focusing on the Mexican case as an emerging market in Latin America. Biotechnol Adv. 2013 Dec;31(8):1333-43.
    • (2013) Biotechnol Adv , vol.31 , Issue.8 , pp. 1333-1343
    • Ibarra-Cabrera, R.1    Mena-Pérez, S.C.2    Bondani-Guasti, A.3    García-Arrazola, R.4
  • 28
    • 85032487459 scopus 로고    scopus 로고
    • Kirchlechner T. Current regulations of biosimilars in the Latin American region. 3rd Annual Drug Information Association (DIA) Latin American Regulatory Conference; 12-15 Apr 2011; Panama City, Panama.
  • 29
    • 84860407952 scopus 로고    scopus 로고
    • Current development in regulation of similar biotherapeutic products in Brazil
    • Castanheira LG, Barbano DB, Rech N. Current development in regulation of similar biotherapeutic products in Brazil. Biologicals. 2011;39(5):308-11.
    • (2011) Biologicals , vol.39 , Issue.5 , pp. 308-311
    • Castanheira, L.G.1    Barbano, D.B.2    Rech, N.3
  • 30
    • 84867841480 scopus 로고    scopus 로고
    • Biosimilars in rheumatology: a view from Latin America
    • Mysler E, Scheinberg M. Biosimilars in rheumatology: a view from Latin America. Clin Rheumatol. 2012;31(9):1279-80.
    • (2012) Clin Rheumatol , vol.31 , Issue.9 , pp. 1279-1280
    • Mysler, E.1    Scheinberg, M.2
  • 31
    • 85032481276 scopus 로고    scopus 로고
    • Dalgaard K, Evers M, Santos da Silva J. Biosimilars seven years on: where are we and what's next? Insights into Pharmaceuticals and Medical Products. February 2013 [homepage on the Internet]. 2013 Feb 12 [cited 2014 May 27]. Available from: http://www.mckinsey.com/~/media/mckinsey/dotcom/client_service/Pharma%20and%20Medical%20Products/PMP%20NEW/PDFs/Biosimilars%20Seven%20years%20on_White%20Paper.ashx
  • 32
    • 85032504672 scopus 로고    scopus 로고
    • Pan American Health Organization. Red PARF Documento Técnico No. 7: Recomendaciones para la Evaluación de Productos Bioterapéuticos Similares (PBS). (Español y portugués). June 2011 [homepage on the Internet]. 2011 Jun 29 [cited 2014 May 27]. Available from: http://www.paho.org/hq./index.php?option=com_docman&task=doc_download&gid=13592&Itemid=&lang=en
  • 33
    • 85032463859 scopus 로고    scopus 로고
    • Saidon P. Level of adoption and implementation of technical document N° 7. VII Conference of the Pan American Network for Drug Regulatory Harmonization; 5-7 September 2013; Ottawa, Canada. [homepage on the Internet]. [cited 2014 May 27]. Available from: http://www.paho.org/hq/index.php?option=com_docman&task=doc_download&gid=22906&Itemid=270&lang=en
  • 34
    • 85032494284 scopus 로고    scopus 로고
    • Knezevic I. WHO Survey on Biotherapeutic Products (focus on clinical issues). VII Conference of the Pan American Network for Drug Regulatory Harmonization. 5-7 September 2013; Ottawa, Canada [homepage on the Internet]. [cited 2014 May 27]. Available from: http://www.paho.org/hq/index.php?option=com_docman&task=doc_download&gid=22904&Itemid=270&lang=en
  • 35
    • 85032489991 scopus 로고    scopus 로고
    • IMS Institute for Health Informatics. The global use of medicines: outlook through 2017. November 2013 [homepage on the Internet]. 2013 Dec 12 [cited 2014 May 27]. Available from: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Global_Use_of_Meds_Outlook_2017/IIHI_Global_Use_of_Meds_Report_2013.pdf
  • 36
    • 85032473985 scopus 로고    scopus 로고
    • ISAGS. Health Council [homepage on the Internet]. [cited 2014 May 27]. Available from: http://www.isags-unasul.org/ interna.asp?lang=2&idarea=37
  • 37
    • 85032470082 scopus 로고    scopus 로고
    • SICA. COMISCA en breve [homepage on the Internet]. [cited 2014 May 27]. Available from: http://www.sica.int/comisca/comisca_enbreve.aspx
  • 38
    • 85032478081 scopus 로고    scopus 로고
    • Pan American Health Organization. Regional Platform on Access and Innovation for Health Technologies [homepage on the Internet]. [cited 2014 May 27. Available from: http://prais.paho.org/rscpaho


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.